Clinical Trials
14 trialsNCT01589861 2026-04-21
PIKHER2
Institut Paoli-Calmettes
Phase 1/2 Terminated
NCT01806649 2021-10-11
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Prince of Songkla University
Phase 2 Terminated
NCT01695473 2021-01-13
Neoadjuvant BKM120 in High-risk Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02614508 2019-09-03
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Emory University
Phase 1 Terminated
NCT01741753 2019-02-05
BKM120+Abiraterone Acetate for Metastatic CRPC
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated
NCT02303041 2019-01-29
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT01820325 2018-10-11
BASALT-2
Novartis
Phase 1 Terminated
NCT01911325 2018-08-14
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Novartis
Phase 1 Terminated
NCT01852292 2018-07-24
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis
Phase 2 Terminated
NCT01870726 2018-05-30
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Novartis
Phase 1/2 Terminated
NCT02487823 2017-11-17
NCMPC-BKM
Institut Paoli-Calmettes
Phase 1 Terminated
NCT01385293 2017-05-19
BKM120 in Metastatic Castration-resistant Prostate Cancer
Duke University
Phase 2 Terminated
NCT01132664 2016-08-17
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Novartis
Phase 1/2 Terminated